A review of international clinical experience with a low-oestrogen oral contraceptive
Nadjafi, C.; Fontanilles, F.; Turri, M.
Schweizerische Rundschau für Medizin Praxis 65(15): 442-445
1976
ISSN/ISBN: 1013-2058 PMID: 981163 Document Number: 98082
854 women received C49'249-Ba for contraceptive purposes over a total of 4478 cycles (average 5.3 cycles each patient). No pregnancies occurred during the treatment. 50% of the women tolerated the drug without any undesirable side effects. 8% of the women discontinued treatment because of negative side effects. 26 negative side effects were reported in 309 (36.6%) of the patients, in a total of 766 (17.1%) cycles. Amenorrhea was observed in 4.1% of the women in 1.3% of the cycles. 24.4% of the patients reported bleeding disorders. Other symptoms were nausea (7.4% of the cycles), fatigue (2.4%), headache (5.4%). Weight gains, elevated blood pressure, libido changes, and disorders in liver, blood coagulation, or lipid serum were slight. Most of these undesired side effects appeared in the early cycles of therapy and decreased or disappeared after continuation of the treatment. Pregnanediol tests showed that the contraceptive effect of C49'249-Ba occurs through changes in the cervix mucus membrane, endometrium as well as by means of ovulation inhibition. In spite of the low estrogen dose, this preparation offers reliable contraceptive protection.